Erythema multiforme may occur repeatedly after recurrent herpes simplex lesions. There is considerable morbidity, and treatment is usually unsatisfactory. We report a case of intractable erythema multiforme after recurrent herpes labialis in which there was sustained benefit from prophylactic topical application of acyclovir.
Case report
A 51-year-old woman began developing erythema multiforme in 1976, coincident with her menopause. Each attack consisted of painful target lesions on the hands, feet, elbows, and knees, usually in association with oral, vaginal, and conjunctival ulceration, and sometimes with headache and general malaise. Attacks began 10 to 14 days after episodes of blistering and crusting around the mouth typical of herpes labialis. On several occasions herpes simplex virus was isolated from these lesions. Initially erythema multiforme occurred every few months, but the frequency and severity increased progressively so that by 1978 she was having erythema multiforme continuously.
Investigations for other possible causes of erythema multiforme were negative. Clq-binding immune complexes were detected at the onset of erythema multiforme but total haemolytic complement, C3, and C4 concentrations were within normal limits. The herpes simplex complement-fixing antibody titre was 1/16 to 1/32. A succession of treatments had little or no effect. Idoxuridine 5 0O in dimethylsulphoxide reduced the severity of the herpes labialis but had no effect on the erythema multiforme; prednisolone 30 mg daily partially suppressed the erythema multiforme; and superficial radiotherapy (total dose 300 rads over four weeks) was followed by a remission lasting three months. In February 1979, within two hours of the onset of herpes labialis, she was treated with intravenous acyclovir (Wellcome) 5 mg/kg eight-hourly for five days. One week later she suffered a further attack of erythema multiforme and a new outbreak of herpes labialis. In April she began applying 5 % topical acyclovir around the mouth five times daily, but after four weeks this was reduced to twice daily. Subsequently she had only one attack of fully developed erythema multiforme, during a period of one month when she stopped using the cream. During the first 10 months of treatment there were several minor episodes of herpes simplex in the nostrils and occasional papular lesions of erythema multiforme on the fingers, but in the ensuing 10 months there were no further lesions.
Comment
A causal relation between erythema multiforme and herpes simplex infection has long been suspected clinically, though the pathogenesis is still not clear. Several studies have indicated that immune complexes detectable in the serum are deposited in the skin transiently in the early stages of erythema multiforme, but the presence of herpes simplex antigen in such complexes remains in doubt.1 Topical treatment of recurrent mucocutaneous herpes simplex lesions with antiviral drugs may reduce the severity of an individual lesion but has little effect on the associated erythema multiforme.
Acyclovir ointment is an effective treatment for ulcerative herpetic keratitis,2 and intravenous acyclovir has proved beneficial as treatment3 4 and as prophylaxis" for immune-compromised patients with herpes simplex lesions. In our patient early intravenous treatment was of no value but when prophylactic topical treatment was adopted the effect was dramatic. There had been no spontaneous remission in the previous three years and the longest period free of lesions was three months, after a course of radiotherapy. That erythema multiforme did not occur during either period when the patient was free of cold sores adds weight to the assumption that they are causally related.
The prophylactic effect of topical acyclovir in this patient was promising and there were no apparent side effects. A controlled trial is now in progress to evaluate the use of topical prophylaxis in patients with frequent mucocutaneous herpes simplex lesions accompanied by complications. non-insulin-dependent diabetics treated with tolbutamide who attended our clinic during the past three months complained of a hot feeling in the face with visible flush after alcohol; other workers have found a similar prevalence.2 Since the relation between tolbutamide-alcohol flushing and chlorpropamide-alcohol flushing is not clear we challenged these two patients with alcohol after differing periods of treatment with tolbutamide, chlorpropamide, and placebo to see whether they produced flushing.
Case report
The two men, aged 55 and 58, had been diagnosed as having diabetes at the ages of 45 and 50 respectively. Neither had a family history of diabetes. One patient (case 1), who was 1350' of ideal body weight, had been treated for a short while after diagnosis with a low-energy diet, but was later put on tolbutamide 250 mg three times daily, and good metabolic control resulted. The other patient (case 2), who was 95°' of ideal body weight, had been treated with tolbutamide 500 mg twice daily as soon as diabetes was diagnosed and remained on this drug. Alcohol flushing tests were performed between 9 and 11 am after (a) two days of treatment and (b) long-term treatment with tolbutamide; after (c) two days, (d) seven days, and (e) 15 days of treatment with chlorpropamide 250 mg daily; and after (f) placebo. A four-day wash-out period preceded tests (b), (c), and (f).
For 30 minutes before and after ingestion of 40 ml sherry skin temperature was monitored (DOPt 100 digital thermometer, Milan) using a small temperature sensor probe fixed with adhesive tape to the left cheek. Room temperature was kept constant at between 20 and 22'C. Both patients' faces flushed, and they described a hot feeling in the face and showed a rise in skin temperature after both long-and short-term treatment with tolbutamide (table) 
